Free Trial

PowerUp Acquisition (PWUP) Competitors

PowerUp Acquisition logo
$0.42 -0.05 (-9.79%)
As of 04/30/2025

PWUP vs. ALLR, NAII, CMMB, EDSA, SLGL, EQ, LPCN, CING, UBX, and BFRG

Should you be buying PowerUp Acquisition stock or one of its competitors? The main competitors of PowerUp Acquisition include Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), Sol-Gel Technologies (SLGL), Equillium (EQ), Lipocine (LPCN), Cingulate (CING), Unity Biotechnology (UBX), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry.

PowerUp Acquisition vs.

PowerUp Acquisition (NASDAQ:PWUP) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, community ranking, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

PowerUp Acquisition's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PowerUp AcquisitionN/A N/A N/A
Allarity Therapeutics N/A -369.67%-100.06%

In the previous week, Allarity Therapeutics had 3 more articles in the media than PowerUp Acquisition. MarketBeat recorded 3 mentions for Allarity Therapeutics and 0 mentions for PowerUp Acquisition. Allarity Therapeutics' average media sentiment score of 0.79 beat PowerUp Acquisition's score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
PowerUp Acquisition Neutral
Allarity Therapeutics Positive

PowerUp Acquisition has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Allarity Therapeutics received 1 more outperform votes than PowerUp Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
PowerUp AcquisitionN/AN/A
Allarity TherapeuticsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

19.2% of PowerUp Acquisition shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 48.0% of PowerUp Acquisition shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PowerUp AcquisitionN/AN/AN/AN/AN/A
Allarity TherapeuticsN/AN/A-$11.90MN/AN/A

Summary

PowerUp Acquisition beats Allarity Therapeutics on 5 of the 8 factors compared between the two stocks.

Get PowerUp Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for PWUP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PWUP vs. The Competition

MetricPowerUp AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ Exchange
Market Cap$3.29M$473.79M$2.02B$7.93B
Dividend YieldN/A7.74%2.70%4.22%
P/E RatioN/A2.4122.4718.54
Price / SalesN/A54.2459.25103.30
Price / CashN/A69.0151.7234.62
Price / BookN/A3.661.994.25
Net IncomeN/A$35.22M-$333.48M$248.18M
7 Day Performance-16.47%1.56%0.49%1.03%
1 Month Performance-26.67%4.34%-0.96%2.70%
1 Year Performance-96.21%24.28%7.77%4.05%

PowerUp Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PWUP
PowerUp Acquisition
N/A$0.42
-9.8%
N/A-96.2%$3.29MN/A0.00N/AHigh Trading Volume
ALLR
Allarity Therapeutics
0.2977 of 5 stars
$1.03
+9.6%
N/A-97.2%$17.53MN/A0.0010
NAII
Natural Alternatives International
0.9836 of 5 stars
$2.61
-6.1%
N/A-52.0%$17.21M$121.85M-2.02290High Trading Volume
CMMB
Chemomab Therapeutics
3.5772 of 5 stars
$1.16
+3.6%
$9.00
+675.9%
+88.9%$16.66MN/A-1.1620Upcoming Earnings
EDSA
Edesa Biotech
3.0994 of 5 stars
$2.38
+5.3%
$21.00
+782.4%
-47.4%$16.64MN/A-1.2720Short Interest ↓
SLGL
Sol-Gel Technologies
2.3593 of 5 stars
$0.59
+6.4%
$5.00
+754.7%
-1.0%$16.30M$11.71M-1.7250Stock Split
News Coverage
Gap Down
High Trading Volume
EQ
Equillium
2.8034 of 5 stars
$0.46
-3.7%
$3.00
+559.1%
-71.9%$16.26M$41.10M-3.2540Upcoming Earnings
Short Interest ↓
Gap Up
LPCN
Lipocine
2.4862 of 5 stars
$3.01
+0.3%
$10.00
+232.2%
-22.9%$16.05M$11.20M-3.9610Upcoming Earnings
Analyst Forecast
News Coverage
CING
Cingulate
2.5124 of 5 stars
$4.07
-4.0%
$30.67
+653.5%
+313.5%$16.04MN/A-0.2820Short Interest ↑
News Coverage
UBX
Unity Biotechnology
4.1167 of 5 stars
$0.94
-3.1%
$5.33
+467.6%
-29.5%$15.85M$240,000.00-0.7260News Coverage
BFRG
Bullfrog AI
0.4714 of 5 stars
$1.66
flat
N/A-42.7%$15.63M$60,000.00-1.954Upcoming Earnings
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:PWUP) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners